Skip to main content

Articles

Page 1 of 65

  1. Migraine is a multiphasic neurovascular disorder, where headache can be succeeded by postdromal symptoms. However, there are limited research on postdromal symptoms. This study aimed to investigate the proport...

    Authors: Janu Thuraiaiyah, Håkan Ashina, Rune Häckert Christensen, Haidar M. Al-Khazali and Messoud Ashina
    Citation: The Journal of Headache and Pain 2024 25:25
  2. Prior research has shown that individual lifestyles were associated with migraine. Yet, few studies focused on combined lifestyles, particularly in Chinese populations. This cross-sectional study aimed to inve...

    Authors: Yunyang Deng, Harry Haoxiang Wang, Fei Wan Ngai, Dexing Zhang, Jing Qin, Xiangyan Chen and Yao Jie Xie
    Citation: The Journal of Headache and Pain 2024 25:24
  3. Medication overuse headache (MOH) was recently shown to be associated with leaky gut in rodents. We aimed to investigate whether chronic migraine (CM) patients with MOH have elevated lipopolysaccharide levels ...

    Authors: Doga Vuralli, Merve Ceren Akgor, Hale Gok Dagidir, Ozlem Gulbahar, Meltem Yalinay and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2024 25:23
  4. About one-third of persons with migraine experience transient neurologic symptoms, referred to as aura. Despite its widespread prevalence, comprehensive clinical descriptions of migraine with aura remain spars...

    Authors: Andreas Vinther Thomsen, Håkan Ashina, Haidar M. Al-Khazali, Kathrine Rose, Rune Häckert Christensen, Faisal Mohammad Amin and Messoud Ashina
    Citation: The Journal of Headache and Pain 2024 25:22
  5. Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendousl...

    Authors: Noor Bruijn, Romy van Lohuizen, Malgorzata Boron, Mira Fitzek, Francesca Gabriele, Giada Giuliani, Laura Melgarejo, Pavel Řehulka, Gabriele Sebastianelli, Paul Triller, Simone Vigneri, Behiye Özcan and Antoinette Maassen van den Brink
    Citation: The Journal of Headache and Pain 2024 25:20
  6. Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in ...

    Authors: Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2024 25:21
  7. Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to un...

    Authors: Tsubasa Takizawa, Takahiro Kitano, Masahiro Iijima, Kanae Togo and Naohiro Yonemoto
    Citation: The Journal of Headache and Pain 2024 25:19
  8. Headache is a common symptom of influenza infection; however, its causes and consequences remain uncertain. In this manuscript, we analyzed which demographic and clinical factors were associated with the prese...

    Authors: David García-Azorín, Laura Santana-López, José Eugenio Lozano-Alonso, Ana Ordax-Díez, Tomas Vega-Alonso, Diego Macias Saint-Gerons, Yésica González-Osorio, Silvia Rojo-Rello, José M. Eiros, Javier Sánchez-Martínez, Álvaro Sierra-Mencía, Andrea Recio-García, Alejandro Martín-Toribio, Ivan Sanz-Muñoz and Ángel Luis Guerrero-Peral
    Citation: The Journal of Headache and Pain 2024 25:18
  9. The pathophysiology of the reversible cerebral vasoconstriction syndrome (RCVS) remains enigmatic and the role of glymphatics in RCVS pathophysiology has not been evaluated. We aimed to investigate RCVS glymph...

    Authors: Chia-Hung Wu, Yu Kuo, Yu-Hsiang Ling, Yen-Feng Wang, Jong-Ling Fuh, Jiing-Feng Lirng, Hsiu-Mei Wu, Shuu-Jiun Wang and Shih-Pin Chen
    Citation: The Journal of Headache and Pain 2024 25:17
  10. To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches.

    Authors: Xinxin Deng, Liying Zhou, Cui Liang, Xue Shang, Xu Hui, Wendi Liu, Shanshan Liang, Yongsheng Wang, Meng Xu, Kangle Guo, Kehu Yang and Xiuxia Li
    Citation: The Journal of Headache and Pain 2024 25:16
  11. Pediatric Migraine Disability Assessment (PedMIDAS) is one of the most frequently used questionnaires to assess disability from migraine in pediatric patients. This work aimed to evaluate the validity and test...

    Authors: Rehab Magdy, Amr Hassan, Zeinab Mohammed, Mohamed A. Abdeltwab, Nawal F. Abdel Ghaffar and Mona Hussein
    Citation: The Journal of Headache and Pain 2024 25:15
  12. Several risk factors are associated with the chronic evolution of migraine. Clinical and preclinical studies have provided data about the role of hypertension (HT) as one of the potential modifiable risk facto...

    Authors: Federico Mazzacane, Gloria Vaghi, Matteo Cotta Ramusino, Giulia Perini and Alfredo Costa
    Citation: The Journal of Headache and Pain 2024 25:13
  13. Chronic migraine (CM) is a disabling condition with high prevalence in the general population. Until the recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (Anti-CGRP mAbs),...

    Authors: Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2024 25:14
  14. Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient’s features such as those related to an impaired quality of life, due to loss of social life an...

    Authors: Claudio Tana, Bianca Raffaelli, Marcio Nattan Portes Souza, Elena Ruiz de la Torre, Daniel Gams Massi, Najib Kisani, David García-Azorín and Marta Waliszewska-Prosół
    Citation: The Journal of Headache and Pain 2024 25:12

    The Review to this article has been published in The Journal of Headache and Pain 2023 24:167

  15. Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disor...

    Authors: Jakob Paungarttner, Martina Quartana, Lucrezia Patti, Barbora Sklenárová, Fatemeh Farham, Inés Hernando Jiménez, M. Gokcen Soylu, Irina Maria Vlad, Semih Tasdelen, Teresa Mateu, Oreste Marsico, Federica Reina, Viktoria Tischler and Christian Lampl
    Citation: The Journal of Headache and Pain 2024 25:11
  16. Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive informa...

    Authors: Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca
    Citation: The Journal of Headache and Pain 2024 25:10
  17. Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the b...

    Authors: Nadine Friedrich, Krisztina Németh, Martin Tanner, Judit Rosta, Ildikó Dobos, Orsolya Oszlács, Gábor Jancsó, Karl Messlinger and Mária Dux
    Citation: The Journal of Headache and Pain 2024 25:9
  18. Spreading depolarization (SD), underlying mechanism of migraine aura and potential activator of pain pathways, is known to elicit transient local silencing cortical activity. Sweeping across the cortex, the el...

    Authors: Tatiana M. Medvedeva, Maria P. Smirnova, Irina V. Pavlova and Lyudmila V. Vinogradova
    Citation: The Journal of Headache and Pain 2024 25:8
  19. Migraine is a debilitating neurological disorder with pain profile, suggesting exaggerated mechanosensation. Mechanosensitive receptors of different families, which specifically respond to various mechanical s...

    Authors: Adriana Della Pietra, Laura Gómez Dabó, Petr Mikulenka, Christian Espinoza-Vinces, Doga Vuralli, Isil Baytekin, Paolo Martelletti and Rashid Giniatullin
    Citation: The Journal of Headache and Pain 2024 25:6
  20. Despite hypothalamus has long being considered to be involved in the pathophysiology of cluster headache, the inconsistencies of previous neuroimaging studies and a limited understanding of the hypothalamic ar...

    Authors: Stefania Ferraro, Anna Nigri, Maria Grazia Bruzzone, Jean Paul Medina Carrion, Davide Fedeli, Greta Demichelis, Luisa Chiapparini, Giuseppe Ciullo, Ariosky Areces Gonzalez, Alberto Proietti Cecchini, Luca Giani, Benjamin Becker and Massimo Leone
    Citation: The Journal of Headache and Pain 2024 25:7
  21. Given the findings of central effects of erenumab in the literature, we aimed to conduct a rigorous placebo-controlled, double-blind, randomized study to elucidate whether the observed changes are directly att...

    Authors: Hauke Basedau, Kuan-Po Peng, Marlene Schellong and Arne May
    Citation: The Journal of Headache and Pain 2024 25:5
  22. Neuroinflammation, mediated by the activation of microglia, contributes to central sensitization, which is associated with the development of chronic migraine (CM). TREM1 receptors amplify the inflammatory res...

    Authors: Songtang Sun, Zhenzhen Fan, Xuejiao Liu, Longde Wang and Zhaoming Ge
    Citation: The Journal of Headache and Pain 2024 25:3
  23. The pathogenesis of pediatric migraine remains unclear and presents challenges in diagnosis. Recently, growing evidence has indicated that the gut microbiota can exert modulatory functions at the gut-brain axi...

    Authors: Junhui Liu, Kaiyan Xi, Linlin Zhang, Mugu Han, Qingran Wang and Xinjie Liu
    Citation: The Journal of Headache and Pain 2024 25:2
  24. Prior MRI studies on vestibular migraine (VM) have revealed abnormalities in static regional intrinsic brain activity (iBA) and dynamic functional connectivity between brain regions or networks. However, the t...

    Authors: Xing Xiong, Lingling Dai, Wen Chen, Jiajie Lu, Chunhong Hu, Hongru Zhao and Jun Ke
    Citation: The Journal of Headache and Pain 2024 25:1
  25. The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and serv...

    Authors: Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli…
    Citation: The Journal of Headache and Pain 2024 25:4
  26. Half of the sufferers of reversible cerebral vasoconstriction syndrome (RCVS) exhibit imaging-proven blood-brain barrier disruption. The pathogenesis of blood-brain barrier disruption in RCVS remains unclear a...

    Authors: Yu-Hsiang Ling, Nai-Fang Chi, Li-Ling Hope Pan, Yen-Feng Wang, Chia-Hung Wu, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang and Shih-Pin Chen
    Citation: The Journal of Headache and Pain 2023 24:170
  27. Previous studies have developed the Migraine Aura Complexity Score (MACS) system. MACS shows great potential in studying the complexity of migraine with aura (MwA) pathophysiology especially when implemented i...

    Authors: Katarina Mitrović, Andrej M. Savić, Aleksandra Radojičić, Marko Daković and Igor Petrušić
    Citation: The Journal of Headache and Pain 2023 24:169
  28. Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challen...

    Authors: Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, Roberto De Icco, Alejandro Labastida-Ramirez, Dilara Onan, Raffaele Ornello, Ruth Ruscheweyh, Marta Waliszewska-Prosół, Roberta Messina and Francesca Puledda
    Citation: The Journal of Headache and Pain 2023 24:167

    The Review to this article has been published in The Journal of Headache and Pain 2024 25:12

  29. To identify primary factors contributing to hemodialysis-related headache (HRH) in maintenance hemodialysis (MHD) patients.

    Authors: Yuqin Xiong, Nujia You, Ruoxi Liao, Ling Wu, Yao Liu, Ziying Ling and Yang Yu
    Citation: The Journal of Headache and Pain 2023 24:166
  30. Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the prese...

    Authors: Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote and Lénaïc Monconduit
    Citation: The Journal of Headache and Pain 2023 24:165
  31. Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a netwo...

    Authors: Seyran Naghdi, Martin Underwood, Jason Madan, Anna Brown, Callum Duncan, Manjit Matharu, Aiva Aksentyte, Natasha Davies, Sophie Rees, Andrew Cooklin, Amy Grove and Hema Mistry
    Citation: The Journal of Headache and Pain 2023 24:164
  32. The brain functional network topology in new daily persistent headache (NDPH) is not well understood. In this study, we aim to assess the cortical functional network topological characteristics of NDPH using n...

    Authors: Dong Qiu, Zhaoli Ge, Yanliang Mei, Wei Wang, Zhonghua Xiong, Xiaoshuang Li, Ziyu Yuan, Peng Zhang, Mantian Zhang, Xin Liu, Yaqing Zhang, Xueying Yu, Hefei Tang and Yonggang Wang
    Citation: The Journal of Headache and Pain 2023 24:161
  33. In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical ...

    Authors: Marta Waliszewska-Prosół, Doga Vuralli and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2023 24:163
  34. Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for He...

    Authors: Hema Mistry, Seyran Naghdi, Martin Underwood, Callum Duncan, Jason Madan and Manjit Matharu
    Citation: The Journal of Headache and Pain 2023 24:162
  35. Cutaneous allodynia is highly prevalent among migraineurs and is associated with a poor prognosis. The Allodynia Symptom Checklist (ASC-12) is a comprehensive questionnaire to identify the presence and severit...

    Authors: Tetiana Marusich, Tibor M Szikszay, Anne Sennholz, Kerstin Luedtke and Gabriela F. Carvalho
    Citation: The Journal of Headache and Pain 2023 24:160
  36. Primary headache disorder is a known risk factor for stroke in women and usually improves during the first trimester of pregnancy. However, despite this, some women develop headaches during pregnancy (G-HA), a...

    Authors: Ki-Woong Nam, Sungyeon Ha, Min-Jeong Oh, Kyungmi Oh, Chi Kyung Kim, Geum Joon Cho, Young Seo Kim and Cheryl D. Bushnell
    Citation: The Journal of Headache and Pain 2023 24:159
  37. Migraine is a primary headache, which has been producing heavy disease burden globally. There is no data on the incidence of migraine among women of childbearing age worldwide, including China. This study aime...

    Authors: Zhuanzhuan Fan, Jian Kang, Wenting Li, Zhiyong Wang, Huifen Qiao and Fei Xu
    Citation: The Journal of Headache and Pain 2023 24:158
  38. Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population ob...

    Authors: Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta…
    Citation: The Journal of Headache and Pain 2023 24:157
  39. Authors: Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo and Ru-hong Zhang
    Citation: The Journal of Headache and Pain 2023 24:156

    The original article was published in The Journal of Headache and Pain 2023 24:126

  40. Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population h...

    Authors: Messoud Ashina, Stewart J. Tepper, Astrid Gendolla, Bjørn Sperling, Anders Ettrup, Mette Krog Josiassen and Amaal J. Starling
    Citation: The Journal of Headache and Pain 2023 24:155
  41. Women are disproportionately affected by migraine, representing up to 75% of all migraine cases. This discrepancy has been proposed to be influenced by differences in hormone levels between the sexes. One such...

    Authors: Aida Maddahi, Karin Warfvinge, Anja Holm, Jacob C. A. Edvinsson, Philip Victor Reducha, Spyridoula Kazantzi, Kristian A. Haanes and Lars Edvinsson
    Citation: The Journal of Headache and Pain 2023 24:154
  42. New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine ...

    Authors: Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs and Mark E. Bensink
    Citation: The Journal of Headache and Pain 2023 24:153
  43. Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migra...

    Authors: M. Lanteri-Minet, R. Fabre, C. Martin, K. Pradat, A. Alchaar, E. Bozzolo, M. L. Duchene, E. K. Van Obberghen, A. Donnet and D. Fontaine
    Citation: The Journal of Headache and Pain 2023 24:152
  44. Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed to characterize the relative frequency and burden of pre- and post-headache symptoms in people with migraine...

    Authors: Richard B. Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L. Reed, Kristina M. Fanning and Dawn C. Buse
    Citation: The Journal of Headache and Pain 2023 24:151
  45. Medication overuse headache (MOH) is a secondary headache that accompanies chronic migraine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used analgesics worldwide and they are known t...

    Authors: Hale Gök Dağıdır, Elif Topa, Doga Vuralli and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2023 24:150
  46. Serum neurofilament light chain (sNfL) can reflect nerve damage. Whether migraine can cause neurological damage remain unclear. This study assesses sNfL levels in migraine patients and explores whether there i...

    Authors: Jie Fang, Jielong Wu, Tengkun Zhang, Xiaodong Yuan, Jiedong Zhao, Liangcheng Zheng, Ganji Hong, Lu Yu, Qing Lin, Xingkai An, Chuya Jing, Qiuhong Zhang, Chen Wang, Zhanxiang Wang and Qilin Ma
    Citation: The Journal of Headache and Pain 2023 24:149
  47. Migraine is a common disabling neurological disorder with severe physical and psychological damage, but there is a lack of convenient and effective non-invasive early prediction methods. This study aimed to de...

    Authors: Shaojie Duan, Hui Xia, Tao Zheng, Guanglu Li, Zhiying Ren, Wenyan Ding, Ziyao Wang and Zunjing Liu
    Citation: The Journal of Headache and Pain 2023 24:148
  48. Preliminary evidence suggests that several headache disorders may be associated with glymphatic dysfunction. However, no studies have been conducted to examine the glymphatic activity in migraine chronification.

    Authors: Xue Zhang, Wei Wang, Xiaoyan Bai, Xueyan Zhang, Ziyu Yuan, Bingjie Jiao, Yingkui Zhang, Zhiye Li, Peng Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ruiliang Bai, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:147